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Abstract Patients with end-stage renal disease treated by hemodialysis with bioincompatible membranes are ex-
posed during the dialysis period to acute effects on lung microcirculation, which may result in pulmonary fibrosis and
diffusion defects in long-standing dialysis.To investigate the occurrence of these possible chronic pulmonary alterations,
we determined lung function in patientswith chronic renal failure not undergoing hemodialysis and in patientswho had
been receiving regular hemodialysis both for short and long periods of time. Forty-three patients divided into three
groups were studied:17 patients before dialysis with a mean (SD) creatinine clearance of14.1 (6.8) ml/minl1.73m2,10 pa-
tientsreceivingregularhemodialysis for aperiodof less than12months (mean 6.473.5months), and16 patientsreceiving
regularhemodialysis formorethan 5 years (mean 8.373.6 years).First-usebioincompatiblecellulosicdialysismembranes
were used in all the cases.The following parameters were recorded: forced vital capacity (FVC), forced expiratory vo-
lume in1s (FEV1), totallungcapacity (TLC), residualvolume (RV), carbonmonoxide transfer factor (TLCO), accesible lung
volume (VA), carbonmonoxide transfer factor/accesible lung volume (KCOF that is,TLCO/VA), and arterial blood gases.
Patients receiving regular hemodialysis for more than 5 years showed significantly lower values of TLCO and KCO than
patients before dialysis and patients receiving regular hemodialysis for less than12 months. Seventy-five percent of pa-
tients on long-termhemodialysis hadmarkedly reduced TLCO or KCO values (below 80% of the reference value) as com-
pared with 17% of patients before dialysis and 10% of patients dialyzed for less than 12 months (Po0.001). Differences
among groups for the remaining parameters were not observed. In conclusion, patients undergoing long-term regular
hemodialysis with a bioincompatible membrane showed a selective reduction in pulmonary diffusing capacity possibly
due to chronic pulmonary fibrosis.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1346, available online athttp://www.idealibrary.comon
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¢brosis.INTRODUCTION
Patients with end-stage renal disease treated by hemo-
dialysis are exposed to continuous pulmonary insults of
multifactorial origin (1). Fluid retention predisposes to
pulmonary edema, which occurs more frequently in the
presence of concomitant heart disease (2). Moreover,
pulmonary calci¢cation in chronic dialysis patients has
been associated with ¢brotic changes and pulmonary
dysfunction (3,4). On the other hand, membrane bioin-
compatibility results in the activation of the complement
cascade and simultaneous changes in receptors of cell ad-
hesion molecules within the pulmonary vasculature,Received 9 October 2001, accepted in revised form 27 February 2002
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de Nefrolog|¤a, Hospital Cl|¤nico San Carlos,Mart|¤n Lagos s/n, E-28040
Madrid, Spain.Fax: +34 913303492; E-mail: jaherrero@sensefro.orgwhich in turn leads to pulmonary vascular leukostasis
(5) and signi¢cant pulmonary hypertension (6). Pulmon-
ary vascular leukostasis and pulmonary hypertension
have been implicated in the pathogenesis of hypoxemia
during the hemodialysis session (7,8). Changes in lung
function inducedby hemodialysis using a bioincompatible
membrane have been assessed during the short dialysis
period, but whether these acute e¡ects on lung micro-
circulationhave any long-term signi¢cancewithregard to
possible induction of pulmonary ¢brosis and impairment
of pulmonary di¡using capacity have been scarcerly in-
vestigated.
Taking into account that an analysis of pulmonary dif-
fusing capacity is a reliable non-invasive method for the
studyof pulmonary interstitium, a study was designed to
assess the possible development of pulmonary ¢brotic
changes in patients undergoing long-term hemodialysis
488 RESPIRATORYMEDICINEwith a bioincompatible membrane.To this purpose, car-
bonmonoxide transfer factors, spirometric and plethys-
mographic parameters were measured in patients with
end-stage renal disease receiving hemodialysis with a
bioincompatible membrane for a prolonged period of
time and compared with patients in predialysis situation
andwith patients dialyzed for a short period.
METHODS
Patients
A total of 43 patients with chronic renal failure partici-
pated in a cross-sectional study. Patients were divided
into three groups as follows: patients in group 1 (n=17)
had chronic renal failure with creatinine clearance
o25ml/min/1.73m2 (mean 14.176.8ml/min/1.73m2) and
were followed at regular intervals at the outpatient ne-
phrology clinic of our hospital; patients in group 2 (n=10)
had been receiving regular hemodialysis for a period be-
tween 3 and12 months (mean 6.473.5 months); and pa-
tients in group 3 (n=16) had been receiving regular
hemodialysis for a period of at least 5 years (mean
8.373.6 years). Each patient was informed and they
agreed to participate in the study. The study protocol
was approvedby the Institutional Review Board.
Demographic characteristics of patients and etiology
of renal failure are shown inTable1. In the two groups of
patients on chronic hemodialysis treatment, frequency
of dialysis was three times aweek. All the patients were
dialyzed using bicarbonate-based dialysis £uid. Non-re-
used bioincompatible cellulosic hemodialysismembranes
were employed in all the cases. Patients in group 2 were
dialyzed using either cuprophane (n=5) or rayon-cu-
proammonium (n=5) membranes. Patients in group 3
were dialyzed using cuprophane (n=6), cellulose acetate
(n=5), or rayon-cuproammonium (n=5) membranes. Pa-
tients su¡ering from atrial dysrhythmia,moderate or se-
vere heart disease with systolic dysfunction (fractionalTABLE 1. Details of patients studied
Group1
n= 17
Age, years, mean (SD) 63 (14)
Sex (M/F) 8/9
Diagnoses
Glomerulonephritis 4
Interstitialnephropathy 5
Diabetesmellitus 2
Nephroangiosclerosis 1
Chronic saturnism 1
Adult polycystic kidneys 2
Unknown 2shortening r50% on echocardiography), chronic lung
disease, or treatedwith drugs that can damage the lungs
were excluded. Current smokers and ex-smokers were
also excluded. All patients hadbeen in stable clinical con-
dition for at least 3 months preceding the study. None
had any clinical evidence of heart failure at the time of
the study. Moreover, none of the patients in groups 2
and 3 had had any recent problem with the vascular ac-
cess for hemodialysis or had catheters inserted tem-
porarily or permanently for that purpose.
Baseline M-mode echocardiography was performed
in all the patients. Hematocrit values and serum hemo-
globin concentrations were determined before dialysis.
In all thepatients undergoing on hemodialysis treatment,
urea reduction ratio (URR) was the mean value for last
twomeasurements in the precedingmonths, and the re-
sidual creatinine clearance (Ccr), thevalue obtained in the
last control. Serum calcium and phosphorus concentra-
tions were the mean of three measurements and serum
intactparathyroidhormone (iPTH)was themeanof two
measurements performed within 6 months of starting
the study. Patients in groups 2 and 3 were studied be-
tween12 and18h after the end of hemodialysis session.
Study design
On the day of the study an arterial blood samplewas ta-
ken for bloodgas analyses. A forced spirometry was car-
ried out using a Masterlab model 3.14 spirometer
(Masterlab, Jaeger, Wˇrzburg, Germany). Alveolar gas
exchange was measured by the carbon monoxide sin-
gle-breath test and respiratorymechanics with the Mas-
terlab whole body plethysmograph. The following
parameters were recorded: forced vital capacity (FVC),
forced expiratory volume in1s (FEV1), total lung capacity
(TLC), residual volume (RV), carbon monoxide transfer
factor (TLCO), accessible lung volume (VA), and carbon
monoxide transfer factor/accesible lung volume
(KCOFthat is,TLCO/VA). At least threereproducible testsGroup 2
n= 10
Group 3
n = 16
60 (18) 61 (10)
5/5 4/12
1 3
4 4
0 1
2 0
0 0
3 4
0 3
PULMONARYDIFFUSINGCAPACITYINDIALYSISPATIENTS 489were carried out for each measurement and the best
was recorded.Comparisons weremadewith the normal
ranges from Cotes (9) except for KCO, which is also ex-
pressed as the absolute value. Measured parameters
were within the normal range when values recorded
were480% of the corresponding reference data.
Statistical analysis
Between-group di¡erences were assessed with the
Student’s t-test and the analysis of variance (ANOVA)
for data with normal distribution and with the
Mann^Whitney U-test for data with distributions
departing from normality. Relationships between
continuous variables were assessed with the Pearson
product-moment correlation coe⁄cient (r). Statistical
signi¢cance was set at Po0.05. All the values are
expressed asmeans (SD).
RESULTS
Hemoglobin andhematocrit valueswere similar in all the
groups (Table 2).Thirty-¢ve percent of patients in group
1, 60% in group 2, and 50% in group 3 received treatment
with recombinant human erythropoietin. Mean (7SD)
duration of dialysis sessions was similar among patients
in group 2 (226714min) and group 3 (232718min).
There were no di¡erences in URR either (group 2,
72.472.1% vs group 3, 74.773.4%). However, as
expected,Ccr was signi¢cantly higher in patients in groupTABLE 2. Analyticalparameters andresults of bloodgas analy
Data Group1
n= 17
Hemoglobin (g/dl) 11.1 (1.0)
Hematocrit (%) 32.8 (3.3)
Calcium (mg/dl) 9.3 (0.3)
Phosphorus (mg/dl) 4.8 (0.9)*
Ca P product 44.7 (8.8)*
iPTH (pg/ml) 136.0 (74)***
PaO2 (mmHg) 82.1 (9.9)
PaCO2 (mmHg) 36.3 (3.3)
Bicarbonate (mmol/l) 22.7 (3.0)*,a
pH 7.39 (0.04)*,a
FVC (% predicted) 93.8 (10.6)
FEV1 (% predicted) 92.7 (13.8)
TLC (% predicted) 92.0 (10.2)
RV(% predicted) 104.3 (17.6)
TLCO (% predicted) 106.6 (13.1)**
KCO (% predicted) 104.0 (25.2)*
Values aremeans (SD).
*Po0.05, **Po0.01, and ***Po0.001vsgroup 3.
aPo0.05 vsgroups 2 and 3.2 (1.3270.79ml/min/1.73m2) than in patients in group 3
(0.1970.21ml/min/1.73m2) (Po0.01). Serum phosphorus
concentrations, Ca P product, and iPTH levels were
signi¢cantly higher in patients in 3 as compared with pa-
tients in either group 1 or 2 (Table 2). Thirty percent of
patients in group1, 40% of those in group 2, and 48% of
those in group 3 ful¢lled the criteria of left ventricular
hypertrophy on echocardiography.
As shown inTable 2, PaO2 and PaCO2 levels were si-
milar in all the groups. Although bicarbonate and pH va-
lues were signi¢cantly lower for patients in group1than
for those in the remaining groups, di¡erences of these
parameters between patients in groups 2 and 3 were
not observed. On the other hand, di¡erences among
groups for FVC, FEV1, TLC, or RV were not detected
but TLCO and KCO values were signi¢cantly lower in pa-
tients in group 3 than in the remaining groups (Table 2).
Absolute KCO values were also signi¢cantly reduced in
group 3 as comparedwith groups1and 2 (Fig.1). In group
3 patients, however, no correlation between decreases
in TLCO or KCO and serum concentrations of iPTH or
Ca P product valueswas observed.On the otherhand,
TLCO and KCO values were not signi¢cantly di¡erent in
patients in this group when those with or without left
ventricular hypertrophy were compared. Seventy-¢ve
percent of patients in group 3 had lowTLCO or KCOvalues
(o80% predicted) as compared with 17% of patients in
group1and10%ofpatients in group 2 (Table 3). In relation
to spirometric patterns, 10 (62.5%) patients in group 3
had abnormalKCOwithno changes in other lung function
parameters.ses andpulmonary functiontests
Group 2
n = 10
Group 3
n= 16
10.8 (0.7) 10.7 (1.4)
31.8 (2.3) 32.5 (2.4)
9.4 (0.5) 9.8 (0.8)
4.4 (1.0)** 5.7 (1.0)
41.7 (11.4)** 52.6 (11.4)
198.0 (62)** 387.0 (293)
79.4 (6.9) 78.3 (10.5)
38.1 (8.6) 42.0 (9.6)
25.9 (2.9) 26.2 (2.0)
7.41 (0.05) 7.42 (0.04)
94.8 (19.0) 99.4 (14.4)
96.7 (17.3) 96.5 (17.3)
96.3 (12.1) 93.6 (12.7)
117.1 (22.8) 111.2 (20.8)
110.1 (13.9)*** 86.2 (14.0)
108.1 (23.0)*** 76.0 (12.2)
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This study provides an evidence of pulmonary di¡using
capacity abnormalities in patients with end-stage renal
disease receiving regular hemodialysis for many years. In
most cases, derangement of di¡using capacity was not
associated with changes in respiratory mechanics indi-
cating that some form of selective damage in the alveo-
lo-capillary wall that interferes with alveolar gas
exchange had occurred. The low incidence of these ab-
normalities in patients with long-standing severe kidney
disease not treated with hemodialysis as well as in pa-
tients enrolled on dialysis programs for a short period
of time (o12months) suggests that thepathogenetic fac-
tor(s) involved in di¡using capacity derangements are as-
sociatedwith long-term dialysis treatment.
Parameters of pulmonarydi¡using capacity in patients
with chronic renal failure onhemodialysis programshave
been determined in a number of studies with controver-FIG 1. Absolute values of KCO in the three groups of patients
(*Po0.05 and **Po0.01vsgroup 3).
TABLE 3. Numbers of patients in each groupwith particular ab
Data Group1
n = 17 (%)
Abnormal FEV1or FVC 2 (11.7)
Abnormal TLCor RV 2 (11.7)
Abnormal TLCO or KCO 3 (17.7)**
Normalpattern 14 (82.3)
Obstructive pattern 2 (11.7)
Restrictive pattern 1 (5.8)
Mixed 0
KCO only abnormal 2 (11.7)**
**Po0.01vsgroup 3.sial results. In the study of Bush and Gabriel (10), 70% of
patients with varying degrees of chronic renal failure not
undergoing dialysis and a similar proportion of those in
the hemodialysis program for amean of 2.1years had evi-
dence of pulmonary di¡using capacity abnormalities as
de¢nedbyreductions inTLCO andKCO. It shouldbenoted,
however, that a large proportion of patients in this study
were current smokers or ex-smokers, andmost of them
(90%) had associated spirometric abnormalities. Similar
results were found by others (11).Kao et al. (12) reported
a decrease in alveolar permeability using 99mTc-diethy-
lene triamine pentaacetate (DTPA) radioaerosol inhala-
tion during lung scintigraphy in 24 patients on
hemodialysis, which was not correlated with the length
of time of dialysis treatment. By contrast,Yenicerioglu et
al. (13) also using 99mTc-DTPA lung scintigraphy, did not
observe abnormalities of alveolar permeability in 20 he-
modialysis patients either before or after dialysis ses-
sions. In another study, Dujic et al. (14) found a reduction
of TLCO in 25 patients receiving hemodialysis, which was
related to anemia given that TLCO decrease reversed
with blood transfusion. Chan et al. (15) in patients with
chronic renal failure on hemodialysis, reported TLCO
and RV values in the high normal range of a predicted va-
lue (115.7 and 157.8%, respectively) that showed a trend
towards normalization at 6 months of renal transplanta-
tion.These authors attributedhighTLCO and RV values to
the chronic vascular congestive pulmonary state during
the dialysis period, which would improve following renal
transplantation. It is possible that all these apparently
contradictory results may be explained by di¡erent cri-
teria of patient selection, methodologies, characteristics
of dialysis procedure, and time on dialysis. In our study, in
which the groups of patients were comparable with re-
spect to selection criteria, degree of anemia, and charac-
teristics of the hemodialysis session, two markedly
di¡erent situations were encountered.On the one hand,
patients receivinghemodialysis for a shortperiodof time
showed TLCO and RV values in the upper range of nor-normalities of lung function
Group 2
n= 10 (%)
Group 3
n = 16 (%)
2 (20) 3 (18.7)
1 (10) 2 (12.5)
1 (10)** 12 (75)
8 (80) 13 (81.2)
0 2 (12.5)
1 (10) 1 (6.2)
1 (10) 0
1 (10)** 10 (62.5)
PULMONARYDIFFUSINGCAPACITYINDIALYSISPATIENTS 491mality, which is in agreement with ¢ndings reported by
Chan et al. (15). However, 75% of patients receiving he-
modialysis for a long period of time had decreased TLCO
and KCO values, most of which showed isolated pulmon-
ary di¡using capacity alterations, that is, in the absence
of associated spirometric abnormalities. This suggests
the presence of di¡use interstitial pulmonary disease.
The cause of pulmonary ¢brotic changes in patients
on hemodialysis programsmay have a multifactorial ori-
gin. In the present study, patients with moderate or se-
vere heart disease that may be potential causes of
pulmonary edema, interstitial lesions, and pulmonary
di¡using capacity derangement were excluded. All the
patients were dialyzed using bicarbonate-based dialysis
£uid, so that the e¡ect of acetate on cardiovascular he-
modynamics, pulmonary hemodynamics, and lung func-
tion during the dialysis sessionwas excluded (16,17).
Calci¢cation of the lungs has attracted considerable
clinical attention and this phenomenon has been impli-
cated in the pathogenesis of respiratory impairment in
patients with kidney disease. Di¡erent studies have de-
tected a high prevalence of lung calci¢cations in patients
with kidney disease on dialysis when 99mTc-diphospho-
nate scans are performed, while calci¢cations are rarely
seen on plain radiographs (18^20). The pathogenesis of
these calci¢cations has not been clearly elucidated,
although they are thought to have a multifactorial origin.
Secondary hyperparathyroidism is one of the main me-
chanisms leading to soft tissue calci¢cation in patients
with end-stage renal disease. However, most studies
have failed in ¢nding a relationship between pulmonary
calci¢cation and serum iPTH concentrations or Ca x P
product (3,18,19). In the studyof Jarava etal. (20), patients
with pulmonary calci¢cations detected by 99mTc-dipho-
sphonate scanning were older and showed higher levels
of PTH than patients with negative scans. In our study,
ages of patients in the threegroupswere similar. Patients
who hadbeen on hemodialysis formore than 5 years had
signi¢cantlyhigherCa x Pproduct and serumiPTHlevels
than patients in the remaining two groups but the lackof
correlation between Ca x P product and/or PTH levels
andreductions inTLCO orKCO does not allow to establish
any de¢nite conclusions.
The e¡ect of bioincompatible membranes that had
been used in patients receiving dialysis for many years
on pulmonary function abnormalities and, in particular,
on derangement of pulmonary di¡using capacity, is an-
other factor that should be taken into consideration. In
the course of hemodialysis with bioincompatible mem-
branes, complement-mediated activation of granulo-
cytes and increased expression of adhesion-promoting
molecules, such as Mac-1 (CD11b-CD18) (21^24), CD13
(25), and CD45 (24) has been recognized.We have re-
cently shown that the interaction of C5awith the CD88
cell receptor is involved in the membrane-dependent
granulocyte and monocyte activation (26). Increase inadhesion molecule receptors expression specially Mac-1
has been implicated in the pathogenesis of leukopenia
and marked increase in adhesion of granulocytes to the
endothelium, leading to pulmonary leukosequestration
(22,23,25). In recent years, evidence has accumulated
that other neutrophil e¡ector functions, such as reactive
oxygen intermediate production play an important role
as well (27). In addition to leukostasis with the release of
mediators causing in£ammation in thepulmonarymicro-
circulation, other hemodynamic changes consisting in
pulmonary hypertension secondary to vasoconstriction
occur (6). It has been reported that pulmonary vasocon-
striction is mediated by thromboxane A2 from the lung
and other tissues due to stimulation by complement cas-
cade-derivedproducts (28).Theoretically, itmaybe pos-
tulated that the developmentof pulmonaryhypertension
in each dialysis session using a bioincompatible mem-
brane accompanied by an in£ammatory reaction at the
microcirculation level, may cause chronic lesions in the
alveolo-capillary wall, with collagen deposition resulting
in di¡use interstitial pulmonary disease and impairment
of di¡using capacity, whichmay have occurred in our pa-
tients maintained on hemodialysis for a long period of
time.
We conclude that in patients maintained on hemodia-
lysis for a long time, there is a selective impairment in
pulmonary di¡using capacity. It seems that membrane
bioincompatibilitymaybe an importantcause of di¡using
capacity derangement, although the e¡ect of other fac-
tors cannot be excluded. Further prospective, con-
trolled trials where, as many as possible, a large number
of factorswhichmight a¡ect lung function arekept com-
parable are needed to prove the superiority of biocom-
patible over bioincompatible dialysismembranes.
Acknowledgements
We thank Marta Pulido, MD, for editing the manuscript
and editorial assistance.
REFERENCES
1. De Broe ME. Haemodialysis-induced hypoxaemia. Nephrol Dial
Transplant 1995; 9 (Suppl 2): 173–175.
2. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echographic
disease in patients starting end-stage renal disease therapy. Kidney
Int 1995; 47: 186–192.
3. Conger JD, Hammond WS, Alfrey AC, Contiguglia SR, Stanford
RE, Huffer WE. Pulmonary calcification in chronic dialysis patients.
Clinical and pathologic studies. Ann InternMed 1975; 83: 330–336.
4. Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue
calcification in pediatric patients with end-stage renal disease. Kid-
ney Int 1990; 38: 931–936.
5. Craddock PR, Fehr J, Dalmasso AP, Brigham KL, Jacob HS.
Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting
from complement activation by dialyzer cellophane membranes.
J Clin Invest 1977; 59: 878–888.
492 RESPIRATORYMEDICINE6. Walker JF, Lindsay RM, Sibbald WJ, Linton AL. Blood–dialyzer
interaction: hemodynamic manifestations in an animal model. Artif
Organs 1984; 8: 329–333.
7. De Backer WA, Verpooten GA, Borgonjon DJ, Verniere PA, Lins
RR, De Broe ME. Hypoxemia during hemodialysis: effects of
different membranes and dialysate compositions. Kidnet Int 1983;
23: 738–743.
8. Munger MA, Ateshkadi A, Cheung AK, Flaharty KK, Stoddard GJ,
Marshall EH. Cardiopulmonary events during hemodialysis: effects
of dialysis membranes and dialysate buffers. Am JKidney Dis 2000;
36: 130–139.
9. Cotes SE. Lung function. AssessmentandapplicationinMedicine, 5th
edn. Oxford: Blackwell Scientific Publications, 1993.
10. Bush A, Gabriel R. Pulmonary function in chronic renal failure:
effects on dialysis and transplantation. Thorax 1991; 46: 424–428.
11. Moinard J, Guenard H. Membrane diffusion on the lungs in patients
with chronic renal failure. Eur Respir J 1993; 6: 225–230.
12. Kao CH, Hsu YH, Wang SJ. Evaluation of alveolar permeability and
lung ventilation in patients with chronic renal failure using Tc-99
DTPA radioaerosol inhalation lung scintigraphy. Lung 1996; 174:
153–158.
13. Yenicerioglu Y, Sapak Sahin S, Capa G, et al. Effects of
haemodialysis on pulmonary clearance of Tc-99m diethylene
triamine pentaacetate (DTPA). Scand J Urol Nephrol 2000; 34:
126–130.
14. Dujic Z, Tocilj J, Ljutic D, Eterovic D. Effects of hemodialysis and
anemia on pulmonary diffusing capacity, membrane diffusing
capacity and capillary blood volume in uremic patients. Respiration
1991; 58: 277–281.
15. Chan CH, Lai CK, Li PK, Leung CB, Ho AS, Lai NK. Effect of renal
transplantation on pulmonary function in patients with end-stage
renal failure. Am JNephrol 1996; 16: 144–148.
16. Daugirdas JT, Nawab ZM, Hayashi JA. Hemodialysis hemodynamics
in an animal model: effect of using an acetate-buffered dialysate.
J Lab Clin Med 1986; 107: 517–524.
17. Herrero JA, Trobo JI, Torrente J, etal. Hemodialysis with acetate,
DL-lactate and bicarbonate: a hemodynamic and gasometric study.
Kidney Int 1994; 46: 1167–1177.18. Faubert PE, Shapiro WB, Porush JG, et al. Pulmonary calcification
in hemodialyzed patients detected by 99m diphosphonate scan-
ning. Kidney Int 1980; 18: 95–102.
19. Sa´nchez-Tomero JA, Martı´n-Arriba A, Amores JA, Alvarez MS,
Corbacho L, Tabernero JM. Calcificaciones pulmonares y funcio´n
respiratoria en pacientes con insuficiencia renal cro´nica en
programa de hemodia´lisis. Nefrologia 1989; 9: 287–292.
20. Jarava C, Martı´ V, Gurpegui ML, Merello JI, Rodrı´guez-Quesada B,
Palma A. Pulmonary calcification in chronic dialysis patients
(letter). Nephrol Dial Transplant 1993; 8: 673–674.
21. Himmelfarb J, Zaoui P, Hakim R. Modulation of granulocyte LAM-1
and MAC-1 during dialysisFA prospective, randomized con-
trolled trial. Kidney Int 1992; 41: 388–395.
22. Lundahl J, Hed J, Jacobson SH. Dialysis granulocytopenia is
preceded by an increased surface expression of the adhesion-
promoting glucoprotein Mac-1. Nephron 1992; 61: 163–169.
23. Thylen P, Lundahl J, Fernvik E, Hed J, Svenson SB, Jacobson SH.
Mobilization of an intracellular glycoprotein (Mac-1) on monocytes
and granulocytes during hemodialysis. Am J Nephrol 1992; 12:
393–400.
24. Tielemans CL, Delville JPC, Husson CP, et al. Adhesion molecules
and leukocyte common antigen on monocytes and granulocytes
during hemodialysis. Clin Nephrol 1993; 39: 158–165.
25. Werfel T, Sonntag G, Weber MH, Gotze O. Rapid increases in the
membrane expression of neutral endopeptidase (CD10), amino-
peptidase N (CD13), tyrosine phosphatase (CD45), and Fcg-RIII
(CD16) upon stimulation of human peripheral leukocytes with
human C5a. J Immunol 1991; 147: 3909–3914.
26. Herrero JA, Figueredo MA, Patin˜o J, etal.Marcadores de activacio´n
celular en hemodia´lisis con diferentes membranas (abstract). Ne-
frolog|¤a 2000; 20: 47.
27. Kormoczi GF, Rosenkranz AR, Zlabinger GJ. Polymorphonucelar
granulocyte stimulation by cellulose-based hemodialysis mem-
branes. Clin Chem Lab Med 1999; 37: 351–355.
28. Cheung AK, Baranowski RL, Wayman AL. The role of thrombox-
ane in cuprophan-induced pulmonary hypertension. Kidney Int
1987; 31: 1072–1079.
